Arena Pharmaceuticals (FRA:RN3N) Total Payout Ratio : 0.16 (As of May. 21, 2024)

View and export this data going back to 2000. Start your Free Trial

What is Arena Pharmaceuticals Total Payout Ratio?

Total Payout Ratio is the percent a company has paid to its shareholders through net repurchase of shares and dividends based on its Net Income.

Arena Pharmaceuticals's current Total Payout Ratio is 0.16.

Arena Pharmaceuticals Total Payout Ratio Historical Data

The historical data trend for Arena Pharmaceuticals's Total Payout Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Arena Pharmaceuticals Total Payout Ratio Chart

Arena Pharmaceuticals Annual Data

Trend

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Total Payout Ratio

Get a 7-Day Free Trial

2.68

13.23

0.75

0.16

Arena Pharmaceuticals Quarterly Data
	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21
Total Payout Ratio	Get a 7-Day Free Trial															-	0.91	-0.06	-	-

Competitive Comparison of Arena Pharmaceuticals's Total Payout Ratio

For the Biotechnology subindustry, Arena Pharmaceuticals's Total Payout Ratio, along with its competitors' market caps and Total Payout Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Arena Pharmaceuticals's Total Payout Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Arena Pharmaceuticals's Total Payout Ratio distribution charts can be found below:

* The bar in red indicates where Arena Pharmaceuticals's Total Payout Ratio falls into.

Arena Pharmaceuticals Total Payout Ratio Calculation

Total Payout Ratio is a measurement showing the proportion of earnings a company pays shareholders in the form of dividends and net stock repurchases.

Arena Pharmaceuticals's Total Payout Ratio for the fiscal year that ended in Dec. 2021 is calculated as

Total Payout Ratio	=	- (Repurchase of Stock	+	Issuance of Stock	+	Cash Flow for Dividends)	/	Net Income
	=	- (0	+	87.118	+	0)	/	-545.543
	=	0.16

Arena Pharmaceuticals's Total Payout Ratio for the quarter that ended in Dec. 2021 is calculated as

Total Payout Ratio	=	- (Repurchase of Stock	+	Issuance of Stock	+	Cash Flow for Dividends)	/	Net Income
	=	- (0	+	0	+	0)	/	-137.714
	=	0.00

Arena Pharmaceuticals Total Payout Ratio Related Terms

Thank you for viewing the detailed overview of Arena Pharmaceuticals's Total Payout Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.

Arena Pharmaceuticals (FRA:RN3N) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arena Pharmaceuticals Inc (FRA:RN3N) » Definitions » Total Payout Ratio

Comparable Companies

Traded in Other Exchanges

N/A

Address

136 Heber Avenue, Suite 204, Park City, UT, USA, 84060

Website

https://www.arenapharm.com

Arena Pharmaceuticals is a biotechnology company targeting G-protein-coupled receptors. The company has one internally discovered drug, lorcaserin, which has been approved and is marketed in the U.S. and South Korea to target weight management. It is commercialized under the brand name Belviq. The company is collaborating with Eisai to market Belviq in other countries. It has a presence in Europe through its Swiss subsidiary, Arena GmbH. The company's pipeline contains drugs targeting autoimmune diseases, vascular diseases, thrombotic diseases, dementia-associated psychosis, nervous system issues, and pain.

Arena Pharmaceuticals (FRA:RN3N) Headlines

No Headlines